Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

by Stamatovic, Ljiljana , Lambertini, Chiara , DiGiovanna, Michael P. , Schneeweiss, Andreas , Fischer, Hans H. , Wuelfing, Pia , Wapnir, Irene L. , Castro-Salguero, Hugo , Jackisch, Christian , Mamounas, Eleftherios P. , Shao, Zhimin , Brufsky, Adam M. , Guarneri, Valentina , Redondo, Andres , Crown, John P. , Arce-Salinas, Claudia , Restuccia, Eleonora , Hennessy, Bryan T. , Knott, Adam , Nyawira, Beatrice , Geyer, Charles E. , Huang, Chiun-Sheng , Boulet, Thomas , Siddiqui, Asna , Loibl, Sibylle , Fasching, Peter A. , D’Hondt, Véronique , Rota Caremoli, Elena , Conlin, Alison K. , Bonnefoi, Hervé R. , Untch, Michael , Wolmark, Norman , Rastogi, Priya , Mano, Max S.

in Ado-Trastuzumab Emtansine - administration & dosage / Ado-Trastuzumab Emtansine - adverse effects / Adult / Aged / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Biopsy / Breast Cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - mortality / Breast Neoplasms - pathology / Breast Neoplasms - surgery / Cancer therapies / Chemotherapy / Chemotherapy, Adjuvant - methods / Chemotherapy, Adjuvant - statistics & numerical data / Death / Disease-Free Survival / ErbB-2 protein / Estrogens / Female / Follow-Up Studies / Gene amplification / Hematology / Humans / Invasiveness / Kaplan-Meier Estimate / Mastectomy - statistics & numerical data / Middle Aged / Monoclonal antibodies / Neoadjuvant Therapy - methods / Neoplasm Invasiveness - pathology / Neoplasm Invasiveness - prevention & control / Neoplasm Recurrence, Local - epidemiology / Neoplasm Recurrence, Local - prevention & control / Neoplasm, Residual / Oncology / Receptor, ErbB-2 - analysis / Receptor, ErbB-2 - metabolism / Surgery / Survival / Survival analysis / Targeted cancer therapy / Trastuzumab / Trastuzumab - administration & dosage / Trastuzumab - adverse effects / Treatment Outcome / Treatments in Oncology

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

2025

Confirm

Do you wish to request the book?

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Stamatovic, Ljiljana,

Lambertini, Chiara,

DiGiovanna, Michael P.,

Schneeweiss, Andreas,

Fischer, Hans H.,

Wuelfing, Pia,

Wapnir, Irene L.,

Castro-Salguero, Hugo,

Jackisch, Christian,

Mamounas, Eleftherios P.,

Shao, Zhimin,

Brufsky, Adam M.,

Guarneri, Valentina,

Redondo, Andres,

Crown, John P.,

Arce-Salinas, Claudia,

Restuccia, Eleonora,

Hennessy, Bryan T.,

Knott, Adam,

Nyawira, Beatrice,

Geyer, Charles E.,

Huang, Chiun-Sheng,

Boulet, Thomas,

Siddiqui, Asna,

Loibl, Sibylle,

Fasching, Peter A.,

D’Hondt, Véronique,

Rota Caremoli, Elena,

Conlin, Alison K.,

Bonnefoi, Hervé R.,

Untch, Michael,

Wolmark, Norman,

Rastogi, Priya,

Mano, Max S.

2025

Overview

Among persons with residual invasive disease after treatment of HER2-positive early breast cancer, trastuzumab emtansine resulted in 7-year invasive disease–free survival of 80.8%, as compared with 67.1% with trastuzumab.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Ado-Trastuzumab Emtansine - administration & dosage

/ Ado-Trastuzumab Emtansine - adverse effects

/ Adult

/ Aged

/ Antineoplastic Agents, Immunological - adverse effects

/ Antineoplastic Agents, Immunological - therapeutic use

/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage